• Trxade Group’s supplier-to-pharmacy network, delivery services and data analytics platform are empowering independent pharmacies struggling to stay in business amid competitive challenges
• The company reported record revenues of $1.9 million for the most recent quarter, as well as other improvements to its top and bottom lines
• The plight of independent pharmacies has caught the attention of state officials in Illinois, who recently enacted Illinois’ first oversight system for the middlemen who manage pharmacy costs and reimbursement rates

Independent pharmacies in Illinois are celebrating recent state legislative action that strengthens small businesses involved in dispensing quality of life-enhancing medications to their customers, an empowerment trend that pharmaceutical services company Trxade Group Inc. (OTCQB: TRXD) has taken to heart as it builds its own growing network of independent pharmacies across the country.

Many of those mom-and-pop pharmacies have found it necessary to close up shop due to a variety of economic conditions, creating what have come to be known as ‘pharmacy deserts’, where residents remain without close-to-home options for fulfilling their prescription needs, especially if they are looking for a familiar business that knows its neighbors and goes the extra mile to assist them (http://ibn.fm/EVkGM).

Low insurer reimbursement rates have become a common complaint among community-oriented small business pharmacies nationwide. Several pharmacists have blamed the pharmacy benefit manager (PBM) middlemen who negotiate costs between pharmacies and insurers, such as Medicare, Medicaid and commercial health plans, arguing that the PBMs improperly drive up the costs of doing business and thereby force small pharmaceuticals out of business (http://ibn.fm/BGoRl).

Trxade’s network offers a platform for buying medications at competitive prices, as well as services for storing pharmaceuticals and delivering them directly to consumers, with an aim of helping sustain independent pharmacists amid their industry difficulties. Illinois’ legislature provided additional relief that was hailed by the Illinois Pharmacists Association in August by passing a bill that creates its first oversight system for PBMs, as reported by The State Journal-Register (http://ibn.fm/XtEA3). The state has also budgeted millions of dollars for pharmacy assistance out of concern for the small, independent shops, the report states.

Michelle Dyer, who operates three Michelle’s Pharmacy stores in the state, applauded the new law as “a great step to reign in the abusive powers that PBMs use against independent pharmacies,” adding that PBMs are “creating unprofitable environments that make it difficult to sustain business for independent pharmacies, and the result is that we’re seeing these businesses closing all the time in central Illinois,” according to the report.

Trxade’s own private enterprise approach to keeping the lifeblood flowing in independent pharmacies’ veins has seen its financial top and bottom lines grow. Its most recent quarterly report displays record revenue growth, as well as an increase in gross profits and a growing number of subscribers to the pharmacy network.

The company reported that revenues for the three months ended June 30 were over $1.9 million, marking an increase of 129 percent year-over-year. It also marked a 27 percent sequential increase over the first quarter ended March 31 (http://ibn.fm/hOCza).

“We made excellent progress executing against our key strategic priorities in our Delivmeds.com program, our B2C commercial efforts and our proprietary B2B trading platform www.Trxade.com,” Chairman and CEO Suren Ajjarapu stated in a news release. “Accordingly, I am optimistic that our new product lines will generate profitability as increasing pharmaceutical prices drive independent pharmacies, payors and consumers to be more aggressive in sourcing medication.”

For more information, visit the company’s website at www.TrxadeGroup.com

NOTE TO INVESTORS: The latest news and updates relating to TRXD are available in the company’s newsroom at http://ibn.fm/TRXD

• Texas-based Neutra Corp. produces nutraceutical vapor products and is expanding into hemp cultivation and purified hemp extract products
• The wellness product industry measures in the trillions of dollars, growing faster than the global economy, and the hemp cultivation industry is expected to top $26 billion by 2025
• The LOI for Vivis would grant Neutra Corp. an established brand of products built on crystalline CBD and full-spectrum CBD extract, while the J3 Holdings LOI would deliver land, a warehouse and a license to cultivate and refine hemp

The growing focus on health and wellness products and philosophies during recent decades has created a bustling marketplace in which businesses and consumers work collaboratively on wallet-friendly ways to love life in the living of it. Neutra Corp. (OTCQB: NTRR) is an interested player in the arena, advancing its interests in monetizing early stage research and development efforts to build a better human body and global environment by growing vertically within the nutraceuticals, food and drug, and environmental purification sectors.

Neutra Corp. has recently pursued the acquisition of companies that hold licenses to cultivate and process hemp, and to sell established high quality, high potency hemp-extracted products, through letters of intent that would bring the subsidiaries’ strengths into the fold.

The Global Wellness Institute reported last fall that the wellness industry grew by 6.4 percent each year from 2015 to 2017, topping $4.2 trillion as a market growing nearly twice as fast as the global economy (http://ibn.fm/FyvcI) as a result of concerns over the rising costs of health care and growing reporting of select chronic ailments among younger-than-traditional populations. The global hemp industry is expected to experience a CAGR of 34 percent from now to 2025, according to Research and Markets analysts, growing from $4.6 billion to $26.6 billion (http://ibn.fm/yEW8k).

Neutra Corp.’s efforts to develop its portfolio demonstrate its recognition of the market factors in play, as well as its conscientiousness in making a quality of life difference for people. Medical-grade hemp extracts have gained a reputation for helping people to manage pain and anxiety, whether from chronic diseases, athletic injuries or everyday aches and pains.

The company has entered two LOIs for emerging hemp retail brand Vivis and hemp cultivator J3 Holdings. The Vivis acquisition “will give Neutra Corp. an even stronger market presence with an established brand already recognized for superiority,” Neutra Corp. President and CEO Sydney Jim stated in a news release (http://ibn.fm/vtDdG).

Vivis has a product line that uses a 99 percent or higher grade of hemp-extracted crystalline CBD, and the firm is preparing to launch a second brand with an 80 percent or higher grade of full-spectrum CBD extract. Vivis’ extracts are certified by a third-party lab to ensure their quality.

J3 Holdings has land, a warehouse and a license to cultivate and refine hemp that are expected to prove valuable additions to Neutra Corp.’s stable.

For more information, visit the company’s website at www.NeutraInc.com

NOTE TO INVESTORS: The latest news and updates relating to NTRR are available in the company’s newsroom at http://ibn.fm/NTRR

• Renewed health in the oil and gas sectors show an ongoing need for products such as Petroteq Energy’s closed-loop, clean surface extraction CORT operation
• Petroteq is developing what it believes to be the next big thing in the industry after fracking generated a domestic oil production boom in the United States
• While performing maintenance and upgrades at its Utah production site, Petroteq continues to demonstrate its technology’s potential through licensing and lab testing

A new year of continuing recovery in the oil and gas markets has industry watchers enthused about the outlook for U.S. productivity for domestic and international consumers during the coming decades, with production currently hovering at a level of 19-20 million barrels per day. Demand for U.S. oil is “buoyantly very high,” with more than 2.5 million barrels per day of crude oil exported in April, according to Forbes (http://ibn.fm/4BG8v), at a rate that was 35 percent higher than the previous April. Oil product exports, on the other hand, were double that amount.

Petroteq Energy Inc. (TSX.V: PQE) (OTC: PQEFF) is building momentum as an innovator of CORT (Clean Oil Recovery Technology) and is making surface tar sands oil extraction cleaner and simpler than ever. Through a closed-loop recovery process conducted at ground level, Petroteq is removing bituminous oils from the tar sands that are plentiful in Utah’s rural eastern desert and leaving behind sands that are clean enough to grow produce.

CEO David Sealock showcased the operations processes of the company’s two-year labor of love at Utah’s Asphalt Ridge in a video tour of Petroteq’s facilities published in June (http://ibn.fm/qnZwt) in celebration of phase I production.

The company halted operations in order to perform planned equipment re-engineering. The coarseness of the Utah desert sands interfered with initial efforts to arrive at an earlier deadline, but the maintenance alterations to the equipment are expected to decrease the costs of further maintenance in the future and improve the facility’s efficiency in reaching its production goals.

While the facility upgrade advances toward recommencement of production, Petroteq has been pressing the advantages of its technology with other companies in the United States and abroad, approving its first non-exclusive licensing agreement with eastern Texas energy services company Valkor LLC in July and completing demonstrative lab projects for Asian and Australian interests that show the ability of Petroteq’s technology in recovering oil from tar sands and shale (http://ibn.fm/UDwtL).

For more information, visit the company’s website at www.Petroteq.energy

NOTE TO INVESTORS: The latest news and updates relating to PQEFF are available in the company’s newsroom at http://ibn.fm/PQEFF

• More than 70,000 Americans died from drug overdoses in 2017, marking a two-fold increase over the past decade, and preliminary data shows that another 68,000 overdose deaths occurred in 2018
• Another 40,000 people lost their lives in car crashes in 2018, with drugs such as opioids serving as a contributing factor to impaired driving-related fatalities
• The average rate of later opioid dependence and addiction among surgical patients hovered at 12 percent
• Four out of five heroin users first misused prescription opioids, while 11.5 million people misused opioids in 2016
• Endonovo’s SofPulse(R) is clinically proven to significantly speed recovery following surgery, reducing the need for pain medications that can lead to addiction
• The company’s proprietary wearable device can be used for a wide range of medical conditions and is FDA-cleared for treating post-operative pain and edema in soft tissue

Finding answers to the nation’s opioid epidemic is a complex problem being fought on several fronts. In a news release, Alan Collier, chief executive officer of Endonovo Therapeutics Inc. (OTCQB: ENDV), stated that the company’s SofPulse post-operative opioid alternative medical device delivers clinically-proven post-surgical pain relief to patients.

“With the public demanding change and options other than opioids, and with very few alternatives to satisfy those demands, SofPulse is a natural and safe replacement to opioids and a solution to this health crisis,” Collier noted (http://ibn.fm/ksEeK).

Federal statistics show that opioids kill more people per year than car crashes on America’s roadways. An estimated 68,000 Americans died from a drug overdose stemming from opioid abuse in the United States in 2018, although that number could rise once final numbers are compiled, according to Centers for Disease Control and Prevention (CDC) reports (http://ibn.fm/Kd4TZ).

The CDC reported that, in 2016, 11.5 million people misused opioids (http://ibn.fm/NY2Dh), while the Department of Justice reports that four out of five heroin users first misused prescription opioids (http://ibn.fm/meham).

Drug overdose deaths involving any opioid rose from 18,515 deaths in 2007 to 47,600 in 2017, with 68 percent of those deaths occurring among men, per CDC data. In addition, the National Safety Council reports that impaired driving caused by drugs, including opioids, contributed to some of the 40,000 fatal crashes that occurred in each of the past three years (http://ibn.fm/gqf93).

Endonovo’s SofPulse provides targeted pulsed electromagnetic field therapy (tPEMF), which uses targeted microcurrents to transmit gentle pulses to the tissue. Endonovo’s SofPulse is clinically proven to significantly speed the recovery process and reduce the need for potentially addictive pain medications, thereby improving patients’ natural recovery experiences (http://ibn.fm/BxHsd).

Endonovo’s Electroceutical Therapy(TM) is cleared by the U.S. Food and Drug Administration (FDA) for the palliative treatment of post-surgical pain and edema and is CE-marked in the European Economic Area for the promotion of wound healing and the palliative treatment of post-surgical pain and edema. The Centers for Medicare and Medicaid Services also has national coverage determination for the reimbursement of Electroceutical Therapy for the treatment of chronic wounds.

Dr. Peter Novak, who recently joined Endonovo’s scientific advisory board, said he believes that the company’s noninvasive Electroceutical Therapy represents “a fascinating new frontier.” Novak is the director of the Autonomic Laboratory at the Department of Neurology, Brigham and Women’s Hospital in Boston, Massachusetts. He is a board-certified neurologist and a board-certified autonomic specialist.

“Endonovo has assembled a pipeline that approaches compelling pathways from unique angles,” Novak stated in a news release (http://ibn.fm/RPZRt). “There is a major need for therapeutics that improve post-operative recuperation, so I am pleased to join a team that has connected novel science with patient need so clearly.”

For more information, visit the company’s website at www.Endonovo.com

NOTE TO INVESTORS: The latest news and updates relating to ENDV are available in the company’s newsroom at http://ibn.fm/ENDV

• The hemp-derived CBD market is projected to reach $22 billion by 2022
• The company recently entered into a tolling agreement to process five million kilograms of hemp biomass
• HTC has entered into an agreement with Canaccord Genuity Corp. for a C$15 million bought deal private placement

With the passage of the Agriculture Improvement Act of 2018 (commonly known as the 2018 farm bill), hemp production and distribution in the United States became permissible under federal law. Freed from its legal shackles, the industry is experiencing rapid growth. As production and distribution of hemp increases, the business of extracting CBD from hemp biomass, as opposed to extraction from marijuana, is looking more feasible, so much so that industry analyst Brightfield Group projects that the hemp-derived CBD (cannabidiol) market will grow to $22 billion by 2022 (http://ibn.fm/xD28h). This market expansion is already increasing demand for extraction technology such as the Delta Purification System provided by HTC Extraction Systems (TSX.V: HTC). The company has inked one agreement and is in negotiations with other biomass providers in Canada and the United States.

HTC’s proprietary biomass processing occurs in three phases: pre-oil preparation, oil extraction and oil refinement. During the pre-oil extraction stage, the hemp is pulverized and dried. The resulting biomass is then immersed in ethanol, and the resulting mixture – containing cannabinoids, oils, ethanol and plant liquids – is separated from the plant fibers. During the last phase, the oil is collected, with 90 percent of the ethanol being removed and recycled, resulting in an approximate 50 percent CBD crude oil. The crude is then subjected to further distillation to achieve full spectrum oil (FSO) and/or pure CBD isolate.

HTC recently announced its entry into a hemp biomass tolling agreement, which will involve the processing of hemp biomass for the 2019 crop year (http://ibn.fm/hjw4g). The agreement covers 4,200-5,000 acres of hemp in Saskatchewan, utilizing five varieties of Health Canada-approved cultivars as the genetic foundation. HTC will process an estimated five million kilograms of hemp biomass to extract CBD full-spectrum oil (FSO). The company will be paid a “toll fee,” or a percentage of the extracted CBD FSO distillate, for its processing, extraction, purification and distillation services. Toll fees are payments made to companies that provide specialized manufacturing or processing services.

Additionally, HTC is in negotiations with a large hemp biomass producer that has some 60,000 acres of hemp under cultivation. The company intends to enter into a tolling contract with this producer for production crop years 2019, 2020, 2021 and beyond. Hemp biomass tolling contracts with producers are also being negotiated in the United States for the 2020 hemp-crop growing year, under which HTC will provide local-to-grower, drying-to-biomass storage capability and transportation of dried biomass to an HTC extraction facility.

HTC boosted its capital in 2019 by entering into a letter agreement, with Canaccord Genuity Corp. acting as sole book runner and lead underwriter on behalf of a syndicate of underwriters that have agreed to purchase, subject to completion of due diligence, on a bought-deal, private-placement basis, 15 million units of the company’s common shares, at a price of C$1 per unit for aggregate gross proceeds of C$15 million (http://ibn.fm/ZTiVq).

With such endorsements, HTC seems set to capitalize on the mushrooming hemp biomass extraction business.

For more information, visit the company’s website at www.HTCExtraction.com

NOTE TO INVESTORS: The latest news and updates relating to HTC are available in the company’s newsroom at http://ibn.fm/HTC

• A rapidly aging population and technological advances are contributing to the fast growth of the global pain management device market
• The market is currently dominated by neurostimulation devices, which accounted for half the revenue reported in 2018 – a trend that’s likely to continue over the next few years
• Endonovo Therapeutics is already establishing a leading position in the niche; the company’s SofPulse(R) pain management device has been rolled out in a national network of hospitals, clinics and pain management centers for thorough evaluation

The global pain management device market is anticipated to grow rapidly through 2026, expanding at a CAGR of 13.8 percent to reach $14.55 billion, according to Grand View Research’s recent ‘Pain Management Devices Market Size, Share & Trends Analysis Report’ (http://ibn.fm/0WD5t).

Endonovo Therapeutics Inc. (OTCQB: ENDV), a commercial-stage developer of noninvasive Electroceutical Therapeutic devices that target patient pain and inflammation while supporting wound recovery, has already developed its proprietary bioelectronics pain management device called SofPulse. The FDA-cleared device is proven to decrease pain by reducing swelling (edema) to address multiple medical conditions and help the recovery of patients after surgery.

Several factors will contribute to the sustainable growth of the global pain management device market, such as the rapidly aging population worldwide and the fact that a growing part of the population has started showing a preference for pain management devices over oral drugs administered in the aftermath of a surgical intervention.

Technological advancements in the field will also contribute to the market’s growth by enabling the development of more effective devices. There are multiple types of pain management devices. The market is currently dominated by neurostimulation devices, which accounted for over 50 percent of the sector’s revenue generated in 2018. This segment is anticipated to maintain its industry dominance over the forecast period.

Recently, Endonovo announced the rollout of SofPulse in hospital and medical centers across the U.S. The company plans to be in the evaluation stage with 600 hospitals within the next 18 months. “We believe, based on numerous meetings with doctors and hospital administrators, the level of acceptance of our SofPulse device supports our plans to be in hospitals throughout all 50 states by 2020,” Endonovo CEO Alan Collier said in a news release.

The public is demanding pain management options that offer an alternative to opioids. According to a recent Washington Post article (http://ibn.fm/hWkZ6), “Forty-eight states plus around 2,000 local and tribal governments have sued companies in the drug industry, arguing those that make, distribute and sell the drugs are partly responsible for a crisis that has killed more than 400,000 people across the country since 2000, according to the U.S. Centers for Disease Control and Prevention.” However, Collier emphasizes that there are currently very few products that can meet the demand. SofPulse is thus positioned to offer a safe and reliable pain management alternative.

The device works by delivering targeted pulse electromagnetic therapy. Targeted microcurrents deliver gentle pulses to affected tissues, reducing post-surgical pain and decreasing the need for the administration of pharmaceuticals by 2.2 times.

Endonovo’s proprietary technology is an effective treatment for inflammatory conditions, cardiovascular diseases and central nervous system disorders. The device has Federal Drug Administration (FDA) clearance for the treatment of post-surgical pain and edema and has also received CE marking in Europe for the promotion of wound healing and the palliative treatment of post-surgical pain and edema.

For more information, visit the company’s website at www.Endonovo.com

NOTE TO INVESTORS: The latest news and updates relating to ENDV are available in the company’s newsroom at  http://ibn.fm/ENDV

• The Green Organic Dutchman is a cannabis-focused research and development company
• The company recently completed its inaugural shipment to the Ontario Cannabis Store, marking its entry into the recreational cannabis market
• TGOD continues to explore strategic worldwide opportunities

The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF) is a leading producer of premium, certified-organic cannabis. Licensed to cultivate medical cannabis under the Access to Cannabis for Medical Purposes Regulations (ACMPR), the company produces organic medical cannabis in small batches using all-natural, organic, craft-growing principles. TGOD recently entered into the recreational cannabis market, where consumers are seeking a premium organic product.

With head offices in Mississauga, Ontario, TGOD has a planned capacity of 219,000 kilograms and is building 1,643,600 square feet of cultivation and processing facilities across Ontario, Quebec, Jamaica and Denmark. TGOD cultivates its cannabis in a proprietary living soil, without irradiation and in accordance with all-natural principles. The company’s growing process has earned organic certification from Pro-Cert and ECOCERT, both of which are leading organic certification organizations (http://ibn.fm/ZS9Ui).

TGOD’s hybrid facilities offer key advantages over outdoor, indoor and greenhouse facilities. Those advantages include advanced humidity, temperature and overall environmental controls relative to traditional greenhouses. Advantages also include highly automated and positive-pressure rooms that lessen the chance of contaminants.

TGOD recently completed its inaugural shipment to the Ontario Cannabis Store, officially marking the company’s entrance into Canada’s recreational market. In today’s increasingly competitive cannabis market, consumers are developing distinct preferences, especially for organic products. A recent study indicated that over 50 percent of consumers are looking for their cannabis to be organic (http://ibn.fm/MahYL), and Ontario consumers are now able to experience TGOD’s acclaimed Unite Organic dried flower. The company’s high-THC (tetrahydrocannabinol) signature strain is available on www.OCS.ca and at select retail locations across the province of Ontario (http://ibn.fm/IoeTF).

“We are thrilled to introduce Unite Organic dried flower to Ontario adult consumers,” TGOD CEO Brian Athaide stated in a news release. “Launched earlier this year with our Grower’s Circle, Unite Organic was highly praised by medical patients. Our small pilot confirmed that market demand for premium certified organic cannabis exceeds available supply.”

In addition, TGOD continues to provide its products to its medicinal patients throughout Canada. TGOD products were initially available only to a small group of medical patients known as the Grower’s Circle. Subsequently, the company also signed supply agreements with the provinces of Alberta and British Columbia.

Growing to scale, TGOD has unique partnerships in place. The company’s partners include international power-management company Eaton Corp., which provides research and optimization that will enable TGOD to have some of the lowest electricity input costs in the business. This is an essential step in the company’s plan to become one of the lowest-cost producers in Canada. Eaton designed TGOD’s power-management system, and TGOD purchases its power from HCE Energy, owned by the city of Hamilton, Ontario. TGOD utilizes Hydro-Quebec in Valleyfield. The company has another key partnership with construction-management firm Ledcor. The focus of this partnership is on ensuring logistical and infrastructure controls. Ledcor specializes in project and construction management, preconstruction services, design-build and general contracting. TGOD’s alliance partners, which also include Neptune, Mediakos and Symrise AG, are industry leaders, enabling the company to achieve its energy and production goals.

TGOD continues to focus on becoming the largest organic cannabis company in the world. By taking advantage of innovative technology and low-cost power solutions, the company offers investors the potential for substantial ROI. With its proven management team, TGOD is positioned for continued expansion and sales across North America, Latin America and Europe, especially considering its recent entry into the recreational cannabis market

For more information, visit the company’s website at www.TGOD.ca

NOTE TO INVESTORS: The latest news and updates relating to TGODF are available in the company’s newsroom at http://ibn.fm/TGODF

• Organigram’s corporate governance distinguishes the company in the cannabis industry
• OGI’s consistent financial performance positions it as an “anomaly in the Canadian cannabis market”
• The company recently upgraded from the TSX Venture Exchange to the Toronto Stock Exchange

Organigram Holdings Inc. (TSX: OGI) (NASDAQ: OGI), the parent company of Organigram Inc., a leading Canadian licensed producer (LP) of premium-quality cannabis and extract-based products, is focused on producing high-quality, indoor-grown cannabis for patients and adult-recreational consumers. Championing that cause is Organigram’s leadership team, a group of seasoned professionals on the forefront of the global cannabis market who bring decades of experience in consumer-packaged goods, and pharma, including a CEO who held the same position at Tilray (NASDAQ: TLRY) before joining Organigram. In addition, the company’s fiscal discipline and execution, as well as its solid corporate governance foundation, distinguish it while some other LPs have met mild to severe consequences for regulatory breaches.

Bloomberg noted that OGI has a fully independent board of directors (excluding CEO Greg Engel), which is a rarity in the cannabis sector. The CEO sees good corporate governance as essential to a well-run pot company. “This is an industry that’s still very much moving from founders and executives being chairmen or multiple insiders on boards,” Engel told Bloomberg (http://ibn.fm/paDcr). “I think some of the challenges we’ve seen in the industry have been because of a lack of governance. You have to have independent governance that has oversight and holds management accountable.”

Along with the company’s impressive corporate governance comes its equally notable — and consistent — financial performance. This is likely due to its team’s adherence to fiscal discipline, something that can be difficult to find in this industry. Bloomberg noted that, with four quarters of profitability under its belt, Organigram Holdings is “an anomaly in the Canadian cannabis market.”

“Organigram has higher margins than most of its peers and one of the lowest costs per gram in the industry even though it grows indoors, generally considered the most expensive method of production,” the report stated. “Chief Executive Officer Greg Engel attributes this to its ability to get higher yields from its pot plants than companies that grow in greenhouses, as well as its automated packaging lines. No other large Canadian pot producer has managed to post such a long string of positive EBITDA.”

In addition, the company recently uplisted to the Toronto Stock Exchange (TSX) from the TSX Venture Exchange (TSX.V) under the symbol ‘OGI’.

“Graduating to the TSX is a significant milestone for us as a corporation,” Engel stated in a news release (http://ibn.fm/g63Gj). “Our stakeholders have an eye on this marketplace, and this graduation will broaden our reach within the investment community and encourage new investors to learn more about our business, our growth plans and corporate objectives.”

As a result of many of these developments, OGI has attracted significant attention. OGI was deemed a “compelling cannabis stock to buy in August” in a recent article distributed by The Motley Fool (http://ibn.fm/3jeGk). “I continue to view the long-term prospects for Organigram in a favorable light,” contributor Keith Speights wrote. “Other Canadian cannabis producers get a lot more hype right now, but Organigram could be a rising star that will attract plenty of attention in the near future. What I really like about Organigram is that its management team exercises fiscal discipline, which is kind of a rarity in the industry.”

Organigram’s primary facility is located in Moncton, New Brunswick, and the company is regulated by the Cannabis Act and the Cannabis Regulations (Canada). Organigram has sales in all 10 Canadian provinces. The company has developed a portfolio of legal, adult-use recreational cannabis brands, including The Edison Cannabis Company, Ankr Organics, Trailer Park Buds and Trailblazer. Additionally, it delivers industry-leading yields and maximizes quality-cannabis production at one of the lowest cultivation costs per gram* among publicly reporting Canadian LPs. Organigram is committed to translating operational excellence into strong financial results and return on investment for shareholders.

* Cultivation cost per gram is a non-IFRS measure. Please see the Company’s latest MD&A.

For more information, visit the company’s website at www.Investors.Organigram.ca

NOTE TO INVESTORS: The latest news and updates relating to OGI are available in the company’s newsroom at http://ibn.fm/OGRMF

• HTC Extraction Systems is an experienced and successful gas, liquids and biomass extractor and refiner using patented technologies for extraction and distillation processes
• HTC is building a 19,000-square-foot GMP Euro-compliant extraction, purification and distillation facility in Saskatchewan, and it is scouting to build another in the United States for hemp extraction services
• The company recently announced a common shares bought deal, whereby, subject to closing, $15 million in aggregate gross proceeds will be added to its bottom line

Extraction and distillation technology developer HTC Extraction Systems (TSX.V: HTC) is celebrating news that a group of underwriters has agreed, subject to due diligence completion, to purchase 15 million units of combined common shares and warrants to purchase further common shares, which, upon closing will amount to an influx of C$15 million in aggregate gross proceeds (http://ibn.fm/KhNtT).

HTC is drawing on a wealth of experience in extraction, purification and distillation and aims to become one of Canada’s largest cannabidiol (CBD) extractors and refiners as it builds a strategy for processing hemp biomass under an infrastructure that will include: a 19,000-square-foot GMP Euro-compliant extraction tolling facility on six acres of land southeast of Regina, Saskatchewan, and a large‐scale extraction facility at a yet-to-be-determined location in the United States, according to a company news release published in June (http://ibn.fm/SM4S1).

Over time, the company has developed and optimized proprietary systems for biomass, gas and liquid extraction, as well as for the distillation of ethanol and ethanol-based solvents used in the extraction process, and those resources provide the backbone of the company’s products and services.

“HTC will continue to drive the business model, where HTC will own physical assets at our extraction and purification facilities while serving the clean energy and hemp biomass industries,” HTC Executive Chairman Lionel Kambeitz stated in the news release. “Our business model calls for both participating equity ownership and tolling revenue.”

In Canada, HTC has an agreement for the 2019 growing season through which it will receive a projected five million kilograms of hemp biomass for extracting CBD full spectrum oil, using Health Canada-approved cultivars. HTC will receive a percentage of the distillate as payment of the tolling fee. Another tolling agreement with a 60,000-acre farm is pending for the 2019, 2020, 2021 and beyond seasons.

The company’s management plans for a facility in the United States that will adapt the scalable production, extraction, purification and distillation techniques that it has developed in Canada. Leveraging their relationships with successful farming leaders, management will draw on standard operating procedures (SOPs) and best practices in genetics, fertility, crop protection and ingredient sales with multi‐year contracts. HTC then intends to pursue plans for two annual crop rotations producing new high-CBD genetic varieties. The company is also continually evaluating potential synergistic technologies that could use distillate chromatography, chemical isolation and molecular distillation for production benefits.

HTC also intends to leverage its relationship with its related entity, Purely Canada Foods, to provide sales and distribution for its Ingredient CBD market under the brands of Purely Canada Hemp, Purely Canada CBD, Purely Canada Cannabinoids and Purely Canada THC. Purely Canada Foods is expected to develop multi-year ingredient supply contracts with its existing and new global food, beverage and animal food industry customers.

For more information, visit the company’s website at www.HTCExtraction.com

NOTE TO INVESTORS: The latest news and updates relating to HTC are available in the company’s newsroom at http://ibn.fm/HTC

• West Coast-based IONIC Brands has focused on vape products for recreational cannabis users, but a new agreement with a Washington-based partner grants it a foothold in the edibles and infused products sectors
• A second agreement between IONIC and an Australian Bluetooth technology producer will grant IONIC’s consumers access to vaporizer tech originally designed to help medical patients control the dosing of their medications
• The agreements mark an expansion of the cannabis holding company’s ability to provide secure dosing to recreational users
• IONIC expects to launch its newest vape product using the technology during the third quarter

Cannabis holding company IONIC Brands Corp. (CSE: IONC) (OTC: IONKF) is expanding its sphere of operations with agreements that enhance the vape manufacturer’s competitiveness in the edibles and infused products markets, as well as technological developments that are expected to provide IONIC’s recreational consumers an innovative experience.

The company announced July 24 that it has completed the previously announced acquisition of Washington-based Natural Extractions Inc., which is doing business as Zoots Premium Cannabis Infused Edibles (http://ibn.fm/fsurk).

Zoots is an edibles company whose product line includes drops, gummies, energy shots and hard candies manufactured to offer consistent and reliable dosing. The products are currently available at licensed recreational cannabis retailers in Illinois, Washington, Colorado and Massachusetts.

“Our top-rated Ionic vaporizer pen targets consumers interested in luxury cannabis products that can be discreetly consumed which make Zoots edibles a natural fit for our brand strategy,” IONIC Brands Chairman and CEO John Gorst stated in a news release. “The Zoots acquisition expands our market segments to the popular edibles space and expands our distribution network throughout the United States.”

Zoots was founded by brothers Dan, Michael and Patrick Devlin, and Dan will continue as the chief operating officer under the agreement. The company’s products feature cannabis oil from Zoots’ proprietary Cypress Extraction system and offer serving sizes as low as 5 mg tetrahydrocannabinol (THC), making it easy for consumers to manage dosage and control over the drug’s effect.

IONIC’s exclusive Heads of Agreement with Lifespot Health Limited (ASX: LSH) is also a significant step toward managing drug dosing (http://ibn.fm/8LVz5). Lifespot’s Bluetooth-enabled vaporizers were developed to help medical patients efficiently manage dosing of their prescriptions for chronic illnesses and unexpected medical conditions on their personal digital devices, including smartphones, tablets and desktop computers. The tech can also be used effectively for recreational cannabis consumption by IONIC’s customers, once the firms complete binding joint venture and distribution agreements.

Lifespot’s software works with enhanced sensor technology to provide self-learning algorithms that make the company’s products user-friendly and analytical.

“Smartphone Bluetooth technology is the future of cannabis delivery and dosing,” Gorst added. “The company is ecstatic to offer consumers advanced delivery technology that, before this agreement, was only available to medical patients. Ionic’s launch and distribution of the Slim-line Vape is expected to start in Q3 2019 in Washington, Oregon, Nevada and California. The Slim-line Vape is the first Bluetooth enabled vaporizer and platform designed specifically for the use of cannabis.”

The agreement also provides a framework for the ongoing development and improvement of cannabis vaporizer technologies for the recreational cannabis vaporizer market. IONIC has completed a purchase order for an initial series of vaporizer and software technologies, and the company plans to begin shipping the product line during the third quarter.

For more information, visit the company’s website at www.IONIC.social

NOTE TO INVESTORS: The latest news and updates relating to IONKF are available in the company’s newsroom at http://ibn.fm/IONKF